More than a year into a strategic pivot to zero in on the multiple myeloma cell therapy Abecma, 2seventy bio is selling ...
Pharmaceutical Technology on MSN2d
BMS to acquire longtime cell therapy partner 2seventy bio for $286mThe deal comes after a challenging few years for 2seventy bio, which had divested research programmes in recent years.
Abecma made $406 million in 2024, of which BMS paid $43 million to 2seventy bio as part of their profit-sharing agreement.
2seventy bio worked with BMS on the development of BCMA-directed CAR-T therapy Abecma (idecabtagene vicleucel), used to treat ...
Insure your 2017 BMS Motorsports for just $75/year.* Savings: We offer low rates and plenty of discounts. More riding freedom: Your UTV is covered in and off your property. OEM parts in repairs: We ...
Insure your 2017 BMS Motorsports for just $75/year.* Savings: We offer low rates and plenty of discounts. More riding freedom: Your UTV is covered in and off your property. OEM parts in repairs: We ...
The deal caps a turbulent three years for 2seventy bio. The company served as the oncology business of Bluebird Bio until Bluebird spun out 2seventy in 2021.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback